Company / Net Income
Adaptimmune Therapeutics PLC Net Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$70.8M
FY2024
5-year range
-$165.5M / -$70.8M
FY2020-FY2024
Trend
+37.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 9 years, ranging from -$165M in FY2022 to -$70M in FY2017.
Based on SEC 10-K filings.
-$71M in FY2024.
Improved from -$165M to -$71M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income increased 37.8% year-over-year.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$70.8M | +37.8% |
| FY2023 | -$113.9M | +31.2% |
| FY2022 | -$165.5M | -4.7% |
| FY2021 | -$158.1M | -21.5% |
| FY2020 | -$130.1M | +5.2% |
| FY2019 | -$137.2M | -43.6% |
| FY2018 | -$95.5M | -36.2% |
| FY2017 | -$70.1M | +2.0% |
| FY2016 | -$71.6M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026